Blood clots from chronic inflammation medication Xeljanz
Patients who take Xeljanz for rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis and experience severe blood clots, cardiovascular disease, or cancer may qualify for a Xeljanz lawsuit.
In the past few years and as recently as September 2021, the FDA has issued drug safety communication warnings about the possible increased risks of Xeljanz use for certain chronic inflammatory conditions. The Food and Drug Administration now confirms the drug may increase a patient’s cardiovascular risk factor, may lead to serious heart-related problems, may lead to an increased risk for cancer, increased risk of blood clots (deep vein thrombosis DVT), and an increased risk of death.
Many unfortunate victims are now enlisting Xeljanz lawyers and law firms to bring forth Xeljanz lawsuits. Plus, two months ago, a study in the New England Journal of Medicine funded by Pfizer also concluded that several medical adverse events, risks of cancers, and cardiovascular issues are more common with tofacitinib, also known as Xeljanz. Get a free case evaluation today!
What’s the issue with Xeljanz?
According to the FDA, there have been over 42,500 reports of negative symptoms and reactions in Xeljanz and Xeljanz XR users since its launch in 2012. Nearly 15,000 of those negative symptoms and reactions were registered as life-threatening, and about 1000 unfortunate deaths including serious heart-related events and risk of blood clots and death.
Unfortunately, patients treated with Xeljanz for various conditions are experiencing similar issues and side effects regardless of whether they’re being treated for ulcerative colitis, severely active rheumatoid arthritis, or other chronic illnesses.
The Food and Drug Administration reported that hundreds of Xeljanz patients have now suffered from Deep vein thrombosis DVT and pulmonary embolism (blood clot in the lungs).